HC Wainwright Issues Negative Outlook for FHTX Earnings

Key Points

• HC Wainwright lowered its Foghorn Therapeutics Q3 2026 EPS estimate to a loss of $0.29 from $0.28, while projecting continued losses through 2030.
• Despite the negative estimate revision, Foghorn reported a quarterly loss of $0.10 per share, beating expectations of $0.24, and revenue of $16.1 million versus the $6.8 million consensus estimate.
• Analyst sentiment remains moderately positive, with a consensus price target of $11.43 and a “Moderate Buy” rating; shares opened at $6.24 and institutional investors own 61.55% of the company.

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - HC Wainwright dropped their Q3 2026 earnings estimates for shares of Foghorn Therapeutics in a report released on Friday, August 7th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.29) per share for the quarter, down from their previous estimate of ($0.28). The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Foghorn Therapeutics' Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.84) EPS, FY2028 earnings at ($0.84) EPS, FY2029 earnings at ($0.84) EPS and FY2030 earnings at ($0.72) EPS.

Other analysts have also recently issued reports about the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Foghorn Therapeutics in a report on Friday, July 17th. Wall Street Zen raised Foghorn Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $11.43.

Foghorn Therapeutics Trading Up 2.8%

Foghorn Therapeutics stock opened at $6.24 on Tuesday. Foghorn Therapeutics has a 12 month low of $3.27 and a 12 month high of $6.95. The stock's 50 day moving average is $4.77 and its 200-day moving average is $4.96. The company has a market capitalization of $370.53 million, a price-to-earnings ratio of -6.37 and a beta of 2.89.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.14. The company had revenue of $16.10 million during the quarter, compared to the consensus estimate of $6.80 million.

Hedge Funds Weigh In On Foghorn Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Brummer Multi Strategy AB bought a new stake in shares of Foghorn Therapeutics during the 4th quarter valued at $25,000. Russell Investments Group Ltd. increased its position in shares of Foghorn Therapeutics by 13,755.0% in the third quarter. Russell Investments Group Ltd. now owns 5,542 shares of the company's stock worth $27,000 after purchasing an additional 5,502 shares during the period. BNP Paribas Financial Markets raised its stake in Foghorn Therapeutics by 48.0% in the third quarter. BNP Paribas Financial Markets now owns 7,103 shares of the company's stock valued at $35,000 after purchasing an additional 2,305 shares in the last quarter. Strs Ohio raised its stake in Foghorn Therapeutics by 120.5% in the fourth quarter. Strs Ohio now owns 8,600 shares of the company's stock valued at $46,000 after purchasing an additional 4,700 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Foghorn Therapeutics by 136.8% during the second quarter. Tower Research Capital LLC TRC now owns 9,213 shares of the company's stock worth $43,000 after purchasing an additional 5,323 shares during the period. Institutional investors own 61.55% of the company's stock.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company's lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source